Fast-read summaries of the latest findings, clinical updates, and research notes — curated from the frontlines of oncology science.
Anticancer Research flagged the widely-shared Hulscher et al. study (84.4% clinical benefit) with a formal Expression of Concern: no control group, self-reported outcomes. The paper has not been retracted as of August 2026.
A 2026 ASCO abstract documents 182 self-reported fenbendazole users at MD Anderson out of 297,223 visits — with 138 different dosing schedules. A prevalence snapshot with major implications for research design.
A July 2026 study from Wrocław found curcumin cut ATP in fibrosarcoma cells by up to 92% and drove 75% into permanent senescence — outperforming four other natural compounds with the best safety profile.
In May 2026, the American Society of Clinical Oncology issued a formal clinical notice recommending against the use of fenbendazole and ivermectin as cancer treatments. We break down what the notice says — and what the emerging observational data shows.
Native curcumin has less than 1% oral bioavailability. A 2025–2026 wave of nanocarrier research (PLGA, liposomes, nanomicelles, stimuli-responsive particles) has achieved up to 178× improvement in plasma AUC. Two nanoformulations — Sinacurcumin and Lipocur — are now in Phase I/II cancer trials.
2025–2026 research confirms methylene blue as a mitochondrial electron shuttle that bypasses Complex I dysfunction, reduces ROS by 55–65%, inhibits tau aggregation, reduces senescent cells by ~28%, and shows early signal in treatment-resistant depression. Phase 3 Alzheimer's results remain mixed.
A prospective observational study of 197 cancer patients published in Anticancer Research (2026) found an 84.4% clinical benefit ratio with a compounded ivermectin + mebendazole regimen. Here is a detailed breakdown of the findings.
A 2026 study in Scientific Reports identified a specific epigenetic mechanism by which curcumin suppresses oral squamous cell carcinoma (OSCC): by downregulating the histone acetyltransferase EP300, curcumin blocks the Warburg effect in oral cancer cells.
2026 reviews and preclinical studies continue to explore methylene blue's dual role as a photodynamic therapy (PDT) sensitizer and metabolic disruptor in cancer cells. Here is a research summary.
In February 2026, the National Cancer Institute announced it had begun preclinical laboratory studies to evaluate ivermectin's potential anticancer properties. This is a significant signal from the world's largest cancer research institution.
Mebendazole crosses the blood-brain barrier — a rare pharmacokinetic advantage for brain tumor drugs. A Johns Hopkins Phase 1 trial confirmed safety at high doses combined with temozolomide. A 2025 study combined MBZ with bumetanide for a dual cytotoxic and anti-invasive effect in glioblastoma.
A 2025 study in Frontiers in Pharmacology traced a precise mechanism: fenbendazole suppresses HK2, triggering caspase-3/GSDME signaling to cause immunogenic pyroptosis in breast cancer cells. Tumor inhibition comparable to cisplatin in mouse xenograft models. Full mechanistic breakdown inside.
